Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)


ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension




The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.

Study Status: Completed


Condition Intervention Phase
Pulmonary Hypertension Drug: Ambrisentan Phase 3

Verified by Gilead Sciences March, 2010

Sponsored by: Gilead Sciences
Information provided by: Gilead Sciences identifier: NCT00091598

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Lewis J. Rubin, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site